Suppr超能文献

HIV-1辅助受体使用情况的体内演变以及对趋化因子介导抑制作用的敏感性。

In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.

作者信息

Scarlatti G, Tresoldi E, Björndal A, Fredriksson R, Colognesi C, Deng H K, Malnati M S, Plebani A, Siccardi A G, Littman D R, Fenyö E M, Lusso P

机构信息

Unit of Immunobiology of HIV, DIBIT, San Raffaele Scientific Institute, Milan, Italy.

出版信息

Nat Med. 1997 Nov;3(11):1259-65. doi: 10.1038/nm1197-1259.

Abstract

Following the identification of the C-C chemokines RANTES, MIP-1alpha and MIP-1beta as major human immunodeficiency virus (HIV)-suppressive factors produced by CD8+ T cells, several chemokine receptors were found to serve as membrane co-receptors for primate immunodeficiency lentiretroviruses. The two most widely used co-receptors thus far recognized, CCR5 and CXCR4, are expressed by both activated T lymphocytes and mononuclear phagocytes. CCR5, a specific RANTES, MIP-1alpha and MIP-1 receptor, is used preferentially by non-MT2-tropic HIV-1 and HIV-2 strains and by simian immunodeficiency virus (SIV), whereas CXCR4, a receptor for the C-X-C chemokine SDF-1, is used by MT2-tropic HIV-1 and HIV-2, but not by SIV. Other receptors with a more restricted cellular distribution, such as CCR2b, CCR3 and STRL33, can also function as co-receptors for selected viral isolates. The third variable region (V3) of the gp120 envelope glycoprotein of HIV-1 has been fingered as a critical determinant of the co-receptor choice. Here, we document a consistent pattern of evolution of viral co-receptor usage and sensitivity to chemokine-mediated suppression in a longitudinal follow-up of children with progressive HIV-1 infection. Viral isolates obtained during the asymptomatic stages generally used only CCR5 as a co-receptor and were inhibited by RANTES, MIP-1alpha and MIP-1beta, but not by SDF-1. By contrast, the majority of the isolates derived after the progression of the disease were resistant to C-C chemokines, having acquired the ability to use CXCR4 and, in some cases, CCR3, while gradually losing CCR5 usage. Surprisingly, most of these isolates were also insensitive to SDF-1, even when used in combination with RANTES. An early acquisition of CXCR4 usage predicted a poor prognosis. In children who progressed to AIDS without a shift to CXCR4 usage, all the sequential isolates were CCR5-dependent but showed a reduced sensitivity to C-C chemokines. Discrete changes in the V3 domain of gp120 were associated with the loss of sensitivity to C-C chemokines and the shift in co-receptor usage. These results suggest an adaptive evolution of HIV-1 in vivo, leading to escape from the control of the antiviral C-C chemokines.

摘要

在确定C-C趋化因子RANTES、MIP-1α和MIP-1β是CD8 + T细胞产生的主要人类免疫缺陷病毒(HIV)抑制因子之后,发现几种趋化因子受体可作为灵长类免疫缺陷慢病毒的膜共受体。迄今为止公认的两种使用最广泛的共受体CCR5和CXCR4,在活化的T淋巴细胞和单核吞噬细胞中均有表达。CCR5是一种特异性的RANTES、MIP-1α和MIP-1受体,优先被非MT2嗜性的HIV-1和HIV-2毒株以及猿猴免疫缺陷病毒(SIV)使用,而CXCR4是C-X-C趋化因子SDF-1的受体,被MT2嗜性的HIV-1和HIV-2使用,但不被SIV使用。其他细胞分布更受限的受体,如CCR2b、CCR3和STRL33,也可作为某些病毒分离株的共受体。HIV-1包膜糖蛋白gp120的第三个可变区(V3)被认为是共受体选择的关键决定因素。在此,我们记录了在对进行性HIV-1感染儿童的纵向随访中,病毒共受体使用情况和对趋化因子介导的抑制敏感性的一致演变模式。在无症状阶段获得的病毒分离株通常仅使用CCR5作为共受体,并受到RANTES、MIP-1α和MIP-1β的抑制,但不受SDF-1的抑制。相比之下,疾病进展后获得的大多数分离株对C-C趋化因子具有抗性,获得了使用CXCR4的能力,在某些情况下还能使用CCR3,同时逐渐失去对CCR5的使用。令人惊讶的是,即使与RANTES联合使用,这些分离株中的大多数对SDF-1也不敏感。早期获得使用CXCR4的能力预示着预后不良。在进展为艾滋病但未转变为使用CXCR4的儿童中,所有连续分离株均依赖CCR5,但对C-C趋化因子的敏感性降低。gp120的V3结构域的离散变化与对C-C趋化因子敏感性的丧失和共受体使用的转变有关。这些结果表明HIV-1在体内的适应性进化,导致其逃避抗病毒C-C趋化因子的控制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验